Functional Areas:
M&A
Screening / Target Identification / CDMO Landscaping / Investment
Prioritization
Company Type:
Pharmaceutical
CDMOs / Small Molecule API & Drug Product Manufacturers
Therapy Area:
Pharmaceutical
Manufacturing / Small Molecule APIs / Drug Development & Manufacturing
Services
Problem Statement
A private
equity investor sought to identify attractive acquisition opportunities within
the US pharmaceutical CDMO market to establish a scalable manufacturing
platform. The mandate focused on identifying differentiated CDMOs with strong
technical capabilities, regulatory track record, and expansion potential across
small molecule API and drug product manufacturing.
Our Approach
We
conducted a comprehensive M&A screening and target assessment exercise
combining market landscaping, operational profiling, and investment
prioritization:
- Mapped
US-based pharmaceutical CDMOs across small molecule API manufacturing,
formulation development, analytical services, and commercial manufacturing
- Screened
companies across parameters including manufacturing capabilities, regulatory
compliance history, customer base, therapeutic exposure, and operational scale
- Identified
and profiled CDMOs with differentiated technical capabilities such as
high-potency APIs, controlled substances handling, spray drying, and
specialized chemistry expertise
- Evaluated
manufacturing footprint, facility infrastructure, capacity utilization, quality
systems, and FDA inspection history
- Assessed
customer diversification, project mix, commercial versus development-stage
exposure, and long-term growth potential
- Analyzed
ownership structures including founder-owned businesses, private platforms, and
carve-out opportunities suitable for platform or add-on acquisitions
- Prioritized
targets based on strategic fit, scalability, regulatory strength, technical
differentiation, and value creation opportunities
- Developed
investment-ready company profiles including operational assessment, strategic
rationale, and acquisition attractiveness
Outcome
- Delivered a
structured landscape of US pharmaceutical CDMOs across key manufacturing and
service segments
- Identified
high-priority platform and add-on acquisition opportunities aligned with the
client’s investment thesis
- Highlighted
differentiated manufacturers with strong regulatory track record and
specialized technical capabilities
- Created a
prioritized acquisition pipeline segmented by manufacturing capability, scale,
and strategic attractiveness
- Enabled accelerated deal sourcing and investment evaluation through actionable target profiles and market intelligence